Bret Jensen
Bret Jensen is the lead equities analyst with Investors Alley. He's the editor of their newsletters including The Growth Stock Advisor and Biotech Gems.
Bret Jensen's Latest Posts
Follow The Money: 8 Stocks With Heavy Insider Buying
Who knows a stock’s growth prospects better than an executive? Chances are not many people, so that’s why Bret Jensen is profiling eight companies seeing huge insider buying over the last couple of months. Such large purchases signal insider confidence that can lead to huge share price gains. The unexpected Trump election victory is still […]
5 Stocks You’ve Never Heard Of Growing Double-Digits
Put some rapid growth into your portfolio with any of the five little-known stocks Bret Jensen recommends buying today. In today’s market, many popular stocks experiencing double-digit growth have been bid up to sky-high valuations but all five of these stocks are considered “Growth at a Reasonable Price.” It looks like profit growth within the […]
6 Undervalued Stocks With Strong Upcoming Catalysts
If all goes well for these six stocks, over the next year they could be worth significantly more than what currently trade for. Each stock has important, business-defining events that, if positive, would make their businesses much more valuable. “Uncertainty is the only certainty there is, and knowing how to live with insecurity is the […]
5 Deeply Undervalued Stocks With Great Dividends
Buy these five stocks today while their yields are high and their shares are cheap. With the rest of the market slightly overbought, purchasing these cheap dividend stocks with above-average yields will put you miles ahead of most investors who chase the hot stock of the minute. Income investors might not have been as comfortable […]
4 Top Biotech Stocks To Be Purchased On The Cheap
Biotech stocks took a tumble last week, but for the long-term investor these valuations are a gift. Snap up shares of these four promising stocks for a discount today and take advantage of these too-low prices. Last week was brutal for biotech investors. The main indices dropped more than six percent just in Tuesday’s and […]
4 Cheap Stocks With Breakout Potential
Offering compelling value and rich upside, two increasingly rare qualities now that the market flirts with all-time highs, these four stocks should either be on your watchlist or in your portfolio. Overpaying for stocks is one of the surest ways to limit your returns. Alcoa (NYSE: AA) opened up third quarter earnings season this week. […]
4 Takeover Targets In The Market’s Hottest Sector
There has been a fast and furious resurgence in M&A in this sector with tens of billions of dollars of deals going down in just the last couple of months. With expectations that dealmaking will continue to increase, consider these four stocks as solid investments with the chance for huge returns if they are purchased […]
Top 3 Predictions For The Market In 2017
Some major themes have developed in the market this year that will carry over into 2017 and change how investors will profit in the market. Bret Jensen shares his top three strategies for which stocks will win and which will lose in 2017. The third quarter has officially wound to a close. The market has […]
4 Must-Own Biotech Stocks As The Sector Comes Charging Back
Up 20% over the last three months, the biotech sector has come roaring back with a vengeance. Given the positive outlook for this sector, Bret Jensen shares his four “must-own” picks through year-end. After three quarters of significantly underperforming the overall market, the biotech sector has roared back in a big way so far in […]
Buy These 3 Stocks Insiders Love
When insiders step up and put millions of their own dollars on the line to purchase company stock, investors should take notice. Don’t wait to only then see these stocks on CNBC rocketing up double-digits, buy shares today. After over two decades of successfully investing in the volatile and lucrative small biotech space, I have […]
The Next 3 Major Biotech Takeover Targets
After record years for deal volume in both 2014 and 2015 in the biotech and pharma industries, M&A transactions have posted a significant decline in the volume of deals so far in 2016 across these industries. As of late August, transactions based on dollar volume were down almost 65% from the same period in 2015. […]
